Search results for "ASTHMA"

showing 10 items of 860 documents

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

Comparison of adjuvant and adjuvant-free murine experimental asthma models

2009

Introduction The most widely used protocol for the induction of experimental allergic airway inflammation in mice involves sensitization by intraperitoneal (i.p.) injections of the antigen ovalbumin (OVA) used in conjunction with the adjuvant aluminium hydroxide (alum). Although adjuvants are frequently used, there are questions regarding the necessity of alum for murine asthma studies due to the non-physiological nature of this chemical. Objective The objective of this study was to compare experimental asthma phenotypes between adjuvant and adjuvant-free protocols of murine allergic airway inflammation in an attempt to develop a standardized alternative to adjuvant use. Method An adjuvant-…

medicine.medical_treatmentC57BL/6Aluminum HydroxideintraperitonealMicechemistry.chemical_compoundImmunology and AllergySensitizationMice Inbred BALB CbiologyAluminium hydroxiderespiratory systemPhenotypemedicine.anatomical_structuresubcutaneousFemaleBronchial HyperreactivityBALB/cAdjuvantInjections IntraperitonealOvalbuminInjections SubcutaneousImmunologyOriginal Articles:Experimental Models of Allergic Diseaseβ-galactosidaseSensitivity and Specificitycomplex mixturesBALB/cadjuvantAdjuvants ImmunologicAntigenmedicineAnimalsSkin TestsAsthmaAlumbusiness.industryanimal modelAllergensbeta-Galactosidasebiology.organism_classificationmedicine.diseaseAsthmabehaviourrespiratory tract diseasesMice Inbred C57BLDisease Models AnimalOvalbuminalumchemistryImmunologybiology.proteinbusinessClinical & Experimental Allergy
researchProduct

Single and Synergistic Effects of Type 2 Cytokines on Eosinophils and Asthma Hallmarks

2020

Abstract The type 2 cytokines IL-5, IL-13, and IL-4 play an important role in the induction and progression of asthma. According to the Global Initiative for Asthma guidelines, blood eosinophil numbers are one marker that helps to guide treatment decisions in patients suffering from severe forms of asthma. Effects of type 2 cytokines were analyzed, alone or in combination, on eosinophils in blood and other compartments and on the development of asthma symptoms. C57BL/6 mice received a single intranasal application of equimolar amounts of IL-5, IL-13, and IL-4, alone or in combination. Numbers, activation state, and migratory behavior of eosinophils in bone marrow (BM), blood, lung, and bron…

medicine.medical_treatmentImmunologyMedizinMice03 medical and health sciencesTh2 Cells0302 clinical medicineMetaplasiamedicineAnimalsHumansImmunology and AllergyEosinophiliaLungCells CulturedAsthmaGoblet cellInterleukin-13Lungmedicine.diagnostic_testbusiness.industryrespiratory systemEosinophilmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsMice Inbred C57BLDisease Models AnimalBronchoalveolar lavagemedicine.anatomical_structureCytokineImmunologyAirway RemodelingFemaleInterleukin-4Interleukin-5medicine.symptombusiness030215 immunologyThe Journal of Immunology
researchProduct

Molekulārās sensibilizācijas profila pret suņiem saistība ar astmas un alerģiska rinīta kontroles rādītājiem

2022

Izpētes objekts Šis pētījums tika veikts, lai novērtētu suņa alergēnu molekulu sensitizāciju saistību ar astmu un alerģisko rinītu. Pētījuma metodoloģija Tika analizēti dati pacientiem, kuriem veikta ALEX vai ALEX2 paneļa testēšana un iegūts sensitizāciju profils katrai suņa alergēna molekulai (Can f 1, Can f 2, Can f 3, Can f 4, Can f 5 un Can f 6). Iegūtie dati tika analizēti kopā ar pacienta datiem par astmu un alerģisko rinītu. Rezultāti Molekulārā sensitizācija pret Can f 1, Can f 2 un Can f 6 uzrādīja statistiski nozīmīgu ietekmi uz astmas risku, taču, kad tika izslēgta sensitizācija pret citu dzīvnieku epitēliju, tikai Can f 1 un Can f 2 uzrādīja statistiski nozīmīgu ietekmi. Arī poz…

molecular testingallergic rhinitisdog allergen moleculesALEXasthmaMedicīna
researchProduct

Paving the way of systems biology and precision medicine in allergic diseases: The MeDALL success story

2016

MeDALL Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 20 (10) -2015 proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy(.) MeDALL linked epidemiological, clinical and basic research using a stepwise, large-scale and integrative approach: precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology omics, IgE measurement using micro-arrays and environmental data(.) Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sensitisation(.) IgE …

multimorbidityBIRTH COHORTIMMUNE-RESPONSESEUROPEAN INNOVATION PARTNERSHIPCHILDHOOD ASTHMAIGE SENSITIZATIONasthmaINTEGRATED CARECHRONIC RESPIRATORY-DISEASESrhinitispolysensitizationATOPIC-DERMATITISIgEIMMUNOLOGICAL REACTIVITYIMMUNOGLOBULIN-E
researchProduct

Disturbi di Personalità in un gruppo di asmatici: studio prospettico con follow up a dieci anni

2004

The aim of our inquiry was to value, through a longitudinal implant with a follow up after ten years if a deficit like asthma could take part in a personality adaptations as a far as to develop a personality disorder. there are two phases of the research. During the first phase were administer to a goup of 58 asthmatic persons and to an equivalent control group: Questionario Scala d'ansia per l'età evolutiva, the childrens depressions scale, the self perception profile for children, the questionnaire of fear and phobia, the family relations test. In the second phase of our inquiry were adiminstered to a group of 39 subject of the original cohort the personality questionary of structured int…

personality disorders asthma defensive strategies
researchProduct

Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma.

2022

Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, …

pharmacogenomicscorticosteroidpharmacogenomictreatmentGenomicsAsthmacorticosteroidschildrenleukotriene antagonists2-agonistPharmacogeneticsasthma children corticosteroids genetics leukotriene antagonists pharmacogenomics treatment β2-agonistsleukotriene antagonistGeneticsHumansgeneticPrecision MedicineChildβ2-agonistsGenetics (clinical)BiomarkersGenes
researchProduct

Design of New Polyaspartamide Copolymers for siRNA Delivery in Antiasthmatic Therapy

2020

Here, a novel protonable copolymer was realized for the production of polyplexes with a siRNA (inhibitor of STAT6 expression in asthma), with the aim of a pulmonary administration. The polycation was synthesized by derivatization of &alpha

polyaspartamidelcsh:RS1-441Pharmaceutical Science02 engineering and technologyArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compoundpolyaminePEG ratioCopolymerpegylationDerivatization030304 developmental biologySTAT6polyplexechemistry.chemical_classification0303 health sciencesintegumentary systemMucinpolyplexesBiological membranePolymerasthma021001 nanoscience & nanotechnologychemistrysiRNABiophysicsPEGylationAmine gas treating0210 nano-technology
researchProduct

An Overview of Asthma and COVID-19: Protective Factors Against SARS-COV-2 in Pediatric Patients.

2021

Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by severe acute respiratory syndrome coronavirus SARS-COV-2. Aberrant innate immunity response and cytokine storm are responsible for the syndrome. Apparently, in asthmatic patients, the inadequate antiviral immune response and the tendency for asthma exacerbation evoked by common respiratory viruses could explain increased susceptibility to SARS-COV-2 infection. However, asthma has not been suggested to be a risk factor in COVID-19 patients. Therefore, in asthmatic patients some potential protective mechanisms against SARS-COV-2 have been hypothesized, like type 2 immune response, number of eosinophils, overproduct…

protective factorMini ReviewProtective factorPediatricsRJ1-570Type 2 immune response03 medical and health sciences0302 clinical medicineImmune systemSettore MED/38 - Pediatria Generale E Specialisticachildrenmedicine030212 general & internal medicineRisk factorAsthmaInnate immune systembusiness.industrySARS-CoV-2COVID-19asthmamedicine.diseaserespiratory tract diseases030228 respiratory systemInfectious disease (medical specialty)ImmunologyPediatrics Perinatology and Child HealthCytokine stormbusinessFrontiers in pediatrics
researchProduct

High training volume is associated with increased prevalence of non-allergic asthma in competitive cross-country skiers.

2022

BackgroundCross-country skiers have a high prevalence of asthma, but its phenotypes and association with success in competitions are not known.ObjectiveTo investigate, by means of a postal survey, the relative proportions of allergic and non-allergic asthma in competitive cross-country skiers compared with the general population, to study how performance level and training volume are related to asthma and its type and to assess the possible risk factors for allergic and non-allergic asthma in competitive skiers.MethodsAll Finnish cross-country skiers enrolled in the largest national competitions in winter 2019 (n=1282), and a random sample (n=1754) of the general population of the same age …

sairastavuusprevalencePhysical Therapy Sports Therapy and Rehabilitation3121 Internal medicinerespiratory tract diseaseshiihtäjät3141 Health care scienceimmune system diseasesnon-allergic asthmaastmaharjoitteluOrthopedics and Sports Medicinecross-country skiershengityselinten taudit315 Sport and fitness scienceshuman activitieshigh training volumehuippu-urheilijatBMJ open sportexercise medicine
researchProduct